{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
deoxycholic acid
to a specific field?
Status:
US Approved OTC
Source:
21 CFR 346.18(a) anorectal:astringent calamine
Source URL:
First marketed in 1921
Class:
PROTEIN
Targets:
Conditions:
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03255070: Phase 1 Interventional Completed Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04311697: Phase 2/Phase 3 Interventional Completed Critical COVID-19 With Respiratory Failure
(2020)
Source URL:
Class:
PROTEIN
Aviptadil, a vasoactive intestinal polypeptide, is a vasodilator and lowers blood pressure if administered intravenously. In 2007, the orphan designation was granted by the European Commission for aviptadil for the treatment of sarcoidosis, a disease of unknown cause that affects many organs and tissues, most commonly the lungs. Sarcoidosis is characterized by specific microscopic lesions called granulomas. Aviptadil is able to influence the immune system that decreases the inflammatory processes seen in sarcoidosis by acting on the white blood cells (lymphocytes and monocytes) involved in the formation of the granulomas. In combination with phentolamine, the drug is used to treat erectile dysfunction. In addition, aviptadil has been studied in phase II clinical trials for patients with respiratory distress syndrome.
Status:
Investigational
Source:
NCT04462536: Phase 3 Interventional Completed Stroke, Acute
(2020)
Source URL:
Class:
PROTEIN
TAT-NR2B9C is a synthetic peptide fusion of the nine C-terminal residues of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor and the cell membrane protein transduction domain of the HIV-1 tat protein. It is a postsynaptic density protein-95 (PSD95) inhibitor with neuroprotective properties. It is under development for the treatment of acute stroke and acute cerebral ischemia.
Status:
Investigational
Source:
INN:thymoctonan [INN]
Source URL:
Class:
PROTEIN
Thymoctonan (also known as Thymic humoral factor γ2 ) is an octapeptide thymic hormone patented by Yeda Research and Development Co. Ltd. as an immunoregulatory agent. In preclinical models, Thymoctonan exerts potent anti-tumor activity in mice and significantly increases the specific cytotoxic response of immune spleen cells. In addition, Thymoctonan treatment improved the competence of immune spleen cells in adoptive immunotherapy when performed in combination with chemotherapy by melphalan. Besides that Thymoctonan enhancing the anti-viral potential of murine cytomegalovirus immune spleen cells. In fatal murine cytomegalovirus infection model, daily injections of Thymoctonan- enhanced murine cytomegalovirus immune spleen cells prevented the development of a fatal disease in 93% of the recipient mice.
Status:
Investigational
Source:
NCT04462536: Phase 3 Interventional Completed Stroke, Acute
(2020)
Source URL:
Class:
PROTEIN
TAT-NR2B9C is a synthetic peptide fusion of the nine C-terminal residues of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor and the cell membrane protein transduction domain of the HIV-1 tat protein. It is a postsynaptic density protein-95 (PSD95) inhibitor with neuroprotective properties. It is under development for the treatment of acute stroke and acute cerebral ischemia.
Status:
Investigational
Source:
NCT04501978: Phase 3 Interventional Completed Covid19
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04032067: Phase 3 Interventional Completed Benign Prostatic Hyperplasia (BPH)
(2019)
Source URL:
Class:
PROTEIN
Tertomotide (also known as GV1001) is a synthetic telomerase-specific peptide vaccine patented by Norsk Hydro Asa for the cancer treatment. The agent was initially developed as a cancer vaccine, for example, against pancreatic and prostate cancer. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with Tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte response against telomerase-expressing cells. Subsequently, in vivo studies have demonstrated the efficacy of Tertomotide in alleviating benign prostatic hyperplasia (BPH) symptoms by reducing the size of the prostate gland. The mechanism of action of Tertomotide has been proposed to be through its dual activity as a GnRH inhibitor and 5a-reductase inhibitor. The GnRH antagonist activity has been established by co-immunoprecipitation assay, demonstrating an interaction between Tertomotide and the GnRH receptor, which was abolished by pre-treatment with anti-GnRH receptor antibody.
Status:
Investigational
Source:
NCT03700294: Phase 1 Interventional Terminated Advanced Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
